Therapeutic blockade of the PD-1/PD-L1 immune checkpoint pathways unleashes CD8+ T cell-mediated immune power against cancer and is a promising clinical anti-tumor therapeutic modality [5, 6]. The gene discussed is CD274; the disease is cancer.